Activity of human serum antibodies in a hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay

The stalk of the influenza virus hemagglutinin (HA) is an attractive target for antibody-based universal influenza virus vaccine development. While antibodies that target this part of the virus can be neutralizing, it has been shown in recent years that Fc receptor-mediated effector functions are of significant importance for the protective effect of anti-stalk antibodies. Several assays to measure Fc-Fc receptor interaction-based effector functions like antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis exist, but they suffer from limitations such as low throughput and high run-to-run variability. Reporter assays for antibody-dependent cellular cytotoxicity based on reporter cells that express luciferase upon engagement of human Fc γ RIIIa with the Fc of antigen-bound antibodies have been developed as well. These reporter assays can be used in a higher throughput setting with limited run-to-run assay variability but since they express only one Fc receptor, their biological relevance is unclear. Here we optimized an antibody-dependent cellular cytotoxicity reporter assay to measure the activity of antibodies to the conserved stalk domain of H1 hemagglutinin. The assay was then correlated to a CD107a-based degranulation assay, and a strong and significant correlation could be observed. This data suggests that the Fc γ Rllla-based reporter assay is a good substitute for functional assays, especially in settings where larger sample numbers need to be analyzed.

[1]  Christopher T. Stamper,et al.  Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial , 2019, The Lancet. Infectious diseases.

[2]  M. Colonna,et al.  The Natural Cytotoxicity Receptors in Health and Disease , 2019, Front. Immunol..

[3]  L. Gresh,et al.  Novel correlates of protection against pandemic H1N1 influenza A virus infection , 2019, Nature Medicine.

[4]  A. García-Sastre,et al.  Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice , 2019, ImmunoHorizons.

[5]  E. Munari,et al.  Human NK cells: surface receptors, inhibitory checkpoints, and translational applications , 2019, Cellular & Molecular Immunology.

[6]  A. García-Sastre,et al.  Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice , 2019, Journal of Virology.

[7]  E. Saphire,et al.  Antibody-mediated protection against Ebola virus , 2018, Nature Immunology.

[8]  Rafael C Prados-Rosales,et al.  Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis. , 2018, Current opinion in immunology.

[9]  J. Ravetch,et al.  Immunological responses to influenza vaccination: lessons for improving vaccine efficacy. , 2018, Current opinion in immunology.

[10]  J. Dye,et al.  Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection , 2018, Cell.

[11]  Taia T. Wang,et al.  The Role of Fc Gamma Receptors in Broad Protection against Influenza Viruses , 2018, Vaccines.

[12]  Caitlin E. Mullarkey,et al.  Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice , 2017, Nature Communications.

[13]  P. Palese,et al.  Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model , 2017, mBio.

[14]  Veronika Chromikova,et al.  Generation of a serum free CHO DG44 cell line stably producing a broadly protective anti-influenza virus monoclonal antibody , 2017, PloS one.

[15]  S. Subramaniam,et al.  Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes , 2017, Nature Microbiology.

[16]  A. García-Sastre,et al.  Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model , 2017, Journal of Virology.

[17]  R. Hai,et al.  Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model , 2017, Journal of Virology.

[18]  T. Surowy,et al.  Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells. , 2017, Journal of immunological methods.

[19]  N. Callewaert,et al.  Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies , 2017, Journal of Virology.

[20]  B. Gunn,et al.  Modulating Antibody Functionality in Infectious Disease and Vaccination. , 2016, Trends in molecular medicine.

[21]  Caitlin E. Mullarkey,et al.  Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus , 2016, Proceedings of the National Academy of Sciences.

[22]  Martin H. Koldijk,et al.  HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids , 2016, Front. Immunol..

[23]  Caitlin E. Mullarkey,et al.  Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact , 2016, Proceedings of the National Academy of Sciences.

[24]  J. Yewdell,et al.  Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge. , 2016, The Journal of infectious diseases.

[25]  Caitlin E. Mullarkey,et al.  Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. , 2016, Cell host & microbe.

[26]  Thomas D. Wu,et al.  Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody , 2016, PLoS pathogens.

[27]  R. Albrecht,et al.  Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection , 2016, PLoS pathogens.

[28]  P. Palese,et al.  Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans , 2016, mBio.

[29]  R. Hai,et al.  Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins , 2016, Journal of Virology.

[30]  F. Cox,et al.  Protection against H5N1 Influenza Virus Induced by Matrix-M Adjuvanted Seasonal Virosomal Vaccine in Mice Requires Both Antibodies and T Cells , 2015, PloS one.

[31]  Quinlin M Hanson,et al.  A perspective on the structure and receptor binding properties of immunoglobulin G Fc. , 2015, Biochemistry.

[32]  J. Wrammert,et al.  Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. , 2015, The Journal of clinical investigation.

[33]  F. Ennis,et al.  Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children. , 2014, Viral immunology.

[34]  K. Broman,et al.  Modified Vaccinia Virus Ankara Encoding Influenza Virus Hemagglutinin Induces Heterosubtypic Immunity in Macaques , 2014, Journal of Virology.

[35]  J. Reichert Antibody Fc: Linking Adaptive and Innate Immunity , 2014, mAbs.

[36]  P. Palese,et al.  Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo , 2014, Nature Medicine.

[37]  T. Friedrich,et al.  Antibody-Dependent Cellular Cytotoxicity Is Associated with Control of Pandemic H1N1 Influenza Virus Infection of Macaques , 2013, Journal of Virology.

[38]  K. Laurie,et al.  Cross-Reactive Influenza-Specific Antibody-Dependent Cellular Cytotoxicity Antibodies in the Absence of Neutralizing Antibodies , 2013, The Journal of Immunology.

[39]  N. S. Laursen,et al.  Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.

[40]  Mark Mulligan,et al.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells , 2012, Proceedings of the National Academy of Sciences.

[41]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[42]  R. Nussenblatt,et al.  Standardizing immunophenotyping for the Human Immunology Project , 2012, Nature Reviews Immunology.

[43]  J. Skehel,et al.  A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.

[44]  M. Bomsel,et al.  The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcγRI-dependent manner , 2011, AIDS.

[45]  W. Fiers,et al.  Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection , 2011, The Journal of Immunology.

[46]  John Steel,et al.  Hemagglutinin-Pseudotyped Green Fluorescent Protein-Expressing Influenza Viruses for the Detection of Influenza Virus Neutralizing Antibodies , 2009, Journal of Virology.

[47]  R. Center,et al.  Rapid Degranulation of NK Cells following Activation by HIV-Specific Antibodies1 , 2009, The Journal of Immunology.

[48]  Lewis L Lanier,et al.  Up on the tightrope: natural killer cell activation and inhibition , 2008, Nature Immunology.

[49]  D. Burton,et al.  Fc receptor but not complement binding is important in antibody protection against HIV , 2007, Nature.

[50]  M. Glennie,et al.  Intimate Cell Conjugate Formation and Exchange of Membrane Lipids Precede Apoptosis Induction in Target Cells during Antibody-Dependent, Granulocyte-Mediated Cytotoxicity1 , 2007, The Journal of Immunology.

[51]  D. Venzon,et al.  A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. , 2006, Journal of immunological methods.

[52]  D. Metzger,et al.  Fc Receptor-Mediated Phagocytosis Makes a Significant Contribution to Clearance of Influenza Virus Infections1 , 2001, The Journal of Immunology.

[53]  D. Davies,et al.  Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodide. , 2001, Journal of immunological methods.

[54]  K. Nagashima,et al.  Direct evidence for release of pore‐forming protein during NK cellular lysis , 1992, Journal of leukocyte biology.

[55]  T. Masuko,et al.  Release of Esterase from Murine Lymphokine‐activated Killer Cells in Antibody‐dependent Cellular Cytotoxic Reaction , 1991, Japanese journal of cancer research : Gann.

[56]  E. Saksela,et al.  A simplified isotope release assay for cell-mediated cytotoxicity against anchorage dependent target cells. , 1977, Journal of immunological methods.

[57]  M. Koopmans,et al.  Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk–Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity , 2017, The Journal of infectious diseases.

[58]  L. Goetsch,et al.  Evaluation of antibody-dependent cell cytotoxicity using lactate dehydrogenase (LDH) measurement. , 2013, Methods in molecular biology.

[59]  C. Pipho,et al.  Use of propidium iodide staining and flow cytometry to measure anti-mediated cytotoxicity: resolution of complement-sensitive and resistant target cells. , 1983, Journal of immunological methods.